Ascendiant Capital Markets Lowers Alzamend Neuro (NASDAQ:ALZN) Price Target to $35.00

Alzamend Neuro (NASDAQ:ALZN) had its price target decreased by Ascendiant Capital Markets from $50.00 to $35.00 in a report released on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Alzamend Neuro Price Performance

Shares of NASDAQ:ALZN opened at $1.46 on Monday. The firm has a fifty day moving average price of $1.68 and a two-hundred day moving average price of $3.44. Alzamend Neuro has a one year low of $1.40 and a one year high of $19.20.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $1.13. Sell-side analysts forecast that Alzamend Neuro will post -14.27 EPS for the current fiscal year.

Institutional Trading of Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC purchased a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro as of its most recent SEC filing. Hedge funds and other institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.